Ascendis Pharma A/S (ASND) News
Track canonical SquawkNews coverage tagged to ASND, Ascendis Pharma A/S. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 33 indexed stories across 16 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The U.S. 10-year Treasury yield broke above 5% on Tuesday, and crude oil stormed past $105 a barrel, a combination that left every major U.S. equity index in the red at midday. President Donald Trump said on Truth Social
LIVE | Sep 15, 2026, 05:27 PM UTC
L
Ascendis Pharma Price Target Maintained With a $287.00/Share by Raymond James
Ratings actions from Benzinga: GMT) Ascendis Pharma Cut to Outperform From Strong Buy by Raymond JamesRatings actions from Benzinga
NEWS | Sep 15, 2026, 02:02 PM UTC
L
ASND: Share buyback, global expansion, and robust pipeline drive strong growth outlook through 2030
Announced a $400 million share buyback and reaffirmed Vision 2030 goals of €5 billion in revenue, driven by three differentiated products and global expansion. Strong product launches, robust pipeline, and regained cardi
EARNINGS | Sep 15, 2026, 01:40 PM UTC
L
Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved
By Katherine HamiltonAscendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk.The Danish company said Monday it can develop, manufacture
NEWS | Sep 14, 2026, 10:35 PM UTC
L
Ascendis Pharma: Board Authorizes Repurchase of Up to $400M of Ordinary Shares >ASND
Ascendis Pharma: Board Authorizes Repurchase of Up to $400M of Ordinary Shares >ASND
EQUITY | Sep 14, 2026, 10:01 PM UTC
L
ASND - Ascendis Announces Planned $400 Million Share Repurchase Program
ASND - Ascendis Announces Planned $400 Million Share Repurchase Program
NEWS | Sep 14, 2026, 10:00 PM UTC
L
ASND - Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
ASND - Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
NEWS | Sep 14, 2026, 10:00 PM UTC
L
Ascendis Pharma SVP & PAO sold 3,000 shares for $810,570
Bodenhoff Mads, an SVP & PAO officer at Ascendis Pharma A/S, sold 3,000 ordinary shares at $270.19 per share for $810,570 on September 8, 2026. After the sale, the reporter no longer directly owns ordinary shares.
EQUITY | Sep 09, 2026, 09:11 PM UTC
L
Ascendis presents first Infant Data from once-weekly TransCon CNP trial
Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment. TransCon CNP increased linear growth in a sentinel cohort, with an improvement in ACH-specific supine l
EQUITY | Sep 09, 2026, 08:02 PM UTC
L
ASND - First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
ASND - First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
EQUITY | Sep 09, 2026, 08:01 PM UTC
L
Ascendis Pharma to participate in Morgan Stanley healthcare conference
Ascendis Pharma (ASND) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 08, 2026, 08:01 PM UTC
M
Ascendis agrees BioMarin Yuviwel royalty terms; infant reACHin data set for ESPE 2026
Ascendis Pharma agreed to pay BioMarin royalties on Yuviwel sales, with patent and litigation claims dismissed. The company will present infant reACHin TransCon CNP data at ESPE 2026 and faced modest analyst target trims
EQUITY | Sep 07, 2026, 11:22 AM UTC
L
Ascendis to share rare endocrinology program data at ESPE 2026
Ascendis Pharma A/S said it will share the latest Endocrinology Rare Disease program data during ESPE 2026, the European Society for Paediatric Endocrinology’s annual congress on September 8.
GEOPOLITICS | Sep 07, 2026, 11:07 AM UTC
L
ASND - Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
ASND - Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
EQUITY | Sep 07, 2026, 11:00 AM UTC
L
Ascendis Pharma maintained as Outperform; Oppenheimer lifts PT to $312
Oppenheimer maintained its Outperform rating on Ascendis Pharma and raised its price target to $312.00 per share from $304.00, according to TradingView News/Benzinga ratings coverage.
EQUITY | Sep 02, 2026, 05:05 PM UTC
L
Morgan Stanley maintains Ascendis Pharma at Overweight; cuts price target
Morgan Stanley maintained Ascendis Pharma at Overweight and cut its price target to $273.00 per share from $275.00, according to Benzinga/TradingView News.
EQUITY | Sep 01, 2026, 04:21 PM UTC
L
Wedbush maintains Ascendis Pharma price target at $327
Wedbush maintained a $327.00/share price target for Ascendis Pharma.
EQUITY | Sep 01, 2026, 12:31 PM UTC
L
Ascendis Pharma Is Maintained at Buy by B of A Securities
Ascendis Pharma Is Maintained at Buy by B of A Securities
EQUITY | Aug 31, 2026, 05:55 PM UTC
L
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
EQUITY | Aug 31, 2026, 05:30 PM UTC
L
Ascendis Pharma maintained at Buy by Stifel
Stifel maintained its Buy rating on Ascendis Pharma, according to TradingView News.
EQUITY | Aug 31, 2026, 05:26 PM UTC
L
Crude oil gains over 2%; Dallas Fed index surges in August
The Dallas Fed's general business activity index for Texas manufacturing rose to 11.6 in August from 1.3 in July, its strongest reading since January 2025.
CENTRAL_BANK | Aug 31, 2026, 04:46 PM UTC
L
HC Wainwright cuts Ascendis Pharma target to $344
HC Wainwright & Co. cut its Ascendis Pharma price target to $344.00/share from $345.00.
EQUITY | Aug 31, 2026, 04:05 PM UTC
M
Ascendis Pharma rallies after binding settlement over Yuviwel patents
Ascendis Pharma shares rose 5.7% to $262.12 on Monday. The move follows a Sunday binding settlement with BioMarin Pharmaceutical to resolve all global patent disputes regarding Yuviwel.
EQUITY | Aug 31, 2026, 02:30 PM UTC
L
HC Wainwright sets Ascendis Pharma price target at $345/share
HC Wainwright & Co. announced a $345.00/share price target for Ascendis Pharma.
EQUITY | Aug 27, 2026, 12:27 PM UTC
L
Ascendis (ASND) to present TransCon CNP Week 104 trial data orally
Ascendis announces an oral presentation of Week 104 data from its pivotal TransCon CNP (navepegritide) trial at ISDS 2026.
EQUITY | Aug 25, 2026, 08:01 PM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
L
Ascendis Pharma reports Q2 2026 financial results
Ascendis Pharma (ASND) reports its second quarter 2026 financial results.
EARNINGS | Aug 13, 2026, 11:31 AM UTC
L
ASND - Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. - Click For R
ASND - Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
EQUITY | Aug 06, 2026, 12:02 PM UTC
L
ASND PT raised from $288 to $306, maintains Buy @ BAML
ASND PT raised from $288 to $306, maintains Buy @ BAML
EQUITY | Jul 14, 2026, 12:25 PM UTC
H
Ascendis Pharma price target raised to $280 from $275 at RBC Capital
RBC Capital raised the firm's price target on Ascendis Pharma to $280 from $275 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has pi
RATES | Jul 07, 2026, 11:28 AM UTC
M
ASND Showcases Treatment
Ascendis to showcase advances in treatment of achondroplasia at ICCBH 2026
EQUITY | Jun 25, 2026, 08:01 PM UTC